Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer

Breast

Volumn 22, Issue S2, 2013, Pages

  Strasser Weippl, Kathrin ^a   Badovinac Crnjevic, Tanja ^b   Fan, Lei ^b   Goss, Paul E ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Breast cancer; Endocrine; Extended treatment

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; ARTICLE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CARPAL TUNNEL SYNDROME; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLUID RETENTION; HOT FLUSH; HUMAN; INSOMNIA; LIBIDO DISORDER; LUNG EMBOLISM; MYALGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; VAGINA DISCHARGE; VASOMOTOR DISORDER;

ADJUVANT; BREAST CANCER; ENDOCRINE; EXTENDED TREATMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONG-TERM CARE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84884710047     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.033     Document Type: Article

References (31)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
2. Kennecke H.F., Olivotto I.A., Speers C., Norris B., Chia S.K., Bryce C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007, 18(1):45-51.
3. Stewart H.J., Prescott R.J., Forrest A.P. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. JNatl Cancer Inst 2001, 93(6):456-462.
4. Tormey D.C., Gray R., Falkson H.C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. JNatl Cancer Inst 1996, 88(24):1828-1833.
5. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the national Surgical adjuvant breast and bowel project B-14 randomized trial. JNatl Cancer Inst 2001, 93(9):684-690.
6. Institute NC Clinical alert: adjuvant therapy of breast cancer - tamoxifen update 1995, [accessed 14.02.13]. http://www.nlm.nih.gov/databases/alerts/tamoxifen.html.
7. Gray R.G., Rea D., Handling K. aTTom (adjuvant Tamoxifen-To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-Preliminary results. JClin Oncol Off J Am Soc Clin Oncol 2008, 26(suppl):10s.
8. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M., et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377(9762):321-331.
9. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561):559-570.
10. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1):45-53.
11. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol Off J Am Soc Clin Oncol 2010, 28(3):509-518.
12. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60-62.
13. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 2003, 349(19):1793-1802.
14. Mamounas E.P., Jeong J.H., Wickerham D.L., Smith R.E., Ganz P.A., Land S.R., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-totreat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol Off J Am Soc Clin Oncol 2008, 26(12):1965-1971.
15. Jakesz R., Greil R., Gnant M., Schmid M., Kwasny W., Kubista E., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007, 99(24):1845-1853.
16. Markopoulos C., Dafni U., Misitzis J., Zobolas V., Tzoracoleftherakis E., Koukouras D., et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res BCR 2009, 11(3):R35.
17. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012, 381(9869):805-816.
18. Jin H., Tu D., Zhao N., Shepherd L.E., Goss P.E. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. JClin Oncol Off J Am Soc Clin Oncol 2012, 30(7):718-721.
19. Ingle J.N., Tu D., Pater J.L., Martino S., Robert N.J., Muss H.B., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 2006, 99(3):295-300.
20. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTGMA.17. J Natl Cancer Inst 2005, 97(17):1262-1271.
21. Pater J., Tu D., Shepherd L., Ingle J.N., Goss P.E. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat 2008, 108(2):265-269.
22. Goss P.E., Ingle J.N., Pater J.L., Martino S., Robert N.J., Muss H.B., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol Off J Am Soc Clin Oncol 2008, 26(12):1948-1955.
23. Goss P.E., Ingle J., Martino S., Robert N., Muss H., Shepherd L., et al. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. San Antonio breast cancer symposium; 2009; San Antonio, TX 2009.
24. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. New Engl J Med 2003, 348(7):618-629.
25. Amir E., Seruga B., Niraula S., Carlsson L., Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. JNatl Cancer Inst 2011, 103(17):1299-1309.
26. van Nes J.G., Fontein D.B., Hille E.T., Voskuil D.W., van Leeuwen F.E., de Haes J.C., et al. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 2012, 134(1):267-276.
27. Reid D.M., Doughty J., Eastell R., Heys S.D., Howell A., McCloskey E.V., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008, 34(suppl 1):S3-18.
28. Sgroi D.S.I., Cuzick J., Zhang Y., Schnabel C.A., Erlander M.G., Goss P.E., Dowsett M. Comparative performance of breast cancer index (BCI) vs. Oncotype Dx and IHC4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: a TransATAC study. Cancer Res 2012, 72(24suppl):S1-S9. abstr.
29. Bartlett J.M., Bloom K.J., Piper T., Lawton T.J., van de Velde C.J., Ross D.T., et al. Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol Off J Am Soc Clin Oncol 2012, 30(36):4477-4484.
30. Ingle J.N., Tu D., Pater J.L., Muss H.B., Martino S., Robert N.J., et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008, 19(5):877-882.
31. Robert F., Goss P.E., Ingle J. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. JClin Oncol Off J Am Soc Clin Oncol 2006, 24:18s.